stage III colon cancer including RS cancer
Conditions
Interventions
Capecitabine is administrated orally as tablets, 2,500 mg/m2 daily for 14 days followed by a 7-days resting period without treatment, as an intermittent therapy in a 3-weeks cycle for 8 treatment cycl
Sponsors
KSCC
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histologically confirmed Colorectal adenocarcinoma 2)Histological Stage III Colon,Rectosigmoid 3)Curative resection with D2 or more lymph node dissection 4)Resection of histological curability A was performed 5)age:20-80years old 6)Performance status(ECOG):0or1 7)No prior chemotherapy and radiotherapy 8)Oral intake is possible 9)Sufficient organ functions 10)Chemotherapy will be started within 8 weeks from operation 11)Written informed consent
Exclusion criteria
Exclusion criteria: 1)Pregnant or nursing 2)Medical history of allergy or hypersensitivity reactions to fluoropyrimidines 3)The past of the internal organ transplant 4)Serious coexisting illness a;severe pulmonary dysfunction b;ileus or colon dysfunction c;uncontrolled diabetes mellitus d;liver cirrhosis e;uncontrolled hypertension f;history of myocardial infarction, unstable angina within 6 months prior to the registration 5)Active synchronous or metachronous malignancy other than carcinoma in situ 6)Uncontrollable infectious disease 7)Not suitable for participating in the study for any other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the rate of completion of treatment as planned | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety Cumulative incidence of Hand-foot syndrome and hepatic dysfunction 3-years disease free survival rate 5-years disease free survival rate 3-years overall survival rate 5-years overall survival rate | — |
Countries
Japan
Contacts
Public ContactKSCC
CReS Kyushu KSCC
Outcome results
None listed